Corbus Pharmaceuticals Holdings, Inc. announced on September 14, 2026, that its Phase 1b clinical trial of CRB-913, a daily oral medication for obesity, achieved positive topline results. The study, known as CANYON-1, was a 16-week, double-blind, placebo-controlled trial designed to evaluate dose-ranging efficacy and safety.
The trial enrolled 254 obese, non-diabetic adult participants across 15 investigational sites in the United States. Participants were randomized into four cohorts receiving either placebo or one of three doses of CRB-913: 20 mg, 40 mg, or 60 mg. The study utilized a titration regimen where all participants began at 20 mg daily and increased every two weeks to their assigned target dose.
Efficacy data showed statistically significant weight loss across all active dose levels compared to placebo. At the 60 mg dose, the least-squares mean percentage change in weight loss from baseline at week 12 was 5.0%. The study also reported that 44.4% of participants in the 60 mg cohort lost at least 5.0% of their body weight, with the highest individual weight loss recorded at 13.4%.
Regarding safety, the company reported that CRB-913 was generally well tolerated. Treatment discontinuations due to adverse events were lower than those seen with a previous cannabinoid CB1 inverse agonist, monlunabant. The company noted that psychiatric adverse events were infrequent and broadly in line with those reported for approved GLP-1 drugs like liraglutide, semaglutide, and tirzepatide. Additionally, gastrointestinal adverse events were reported as mild or moderate and appeared less frequent than those associated with some oral GLP-1 drugs.
The company stated that the data from this trial have been selected for a late-breaking presentation at ObesityWeek 2026, scheduled for November 14–17, 2026. Corbus indicated it plans to engage with the FDA regarding its clinical development plan and expects to initiate a Phase 2 monotherapy study in the first half of 2027.
